|Study Description:||This is a 2 part study. The goal of the first part of this clinical research |
study is to find the highest tolerable dose of ruxolitinib that can be given
with a TKI that you are already taking (such as gleevec, sprycel, or nilotinib)
as part of your standard of care treatment. The goal of the second part of
this study is to learn if this drug combination can help to control CML.
Although you have a good response to therapy, the disease is still detectable
at low levels (this is called "minimal residual disease"). Researchers believe
that eliminating all detectable evidence of disease may decrease the chances
that the leukemia will ever come back. The safety of the drug combination will
also be studied in both parts.
Ruxolitinib is designed to block a protein called Jak2 that may help keep some
leukemia cells alive even with TKI therapy. Blocking this protein may cause
the cells to die.